Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM-TMI + FluBu Conditioning for Allogeneic Transplantation in High Risk AML and MDS
NCT03121014Phase 2Active, not recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Apr 2017
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, busulfan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Illinois Chicago. Started Apr 2017; status: active, not recruiting.
02
Drugs
fludarabinebusulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03121014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121014.